For laboratory research only. Not for human consumption.Our comparison method ↗
Studio-style Deals on Peptides product visual for Peptide 2 (T)

Vial comparison

Peptide 2 (T) prices

Compare Peptide 2 (T) listings by strength, selection and supplier. Inspect the original source behind each price.

1suppliers represented
10source-linked listings
5strengths available

MATCH SIZE AND QUANTITY

Build your comparison.

Daily snapshot · inspect sources

Choose a labeled amount and selection to load matching prices.

GO BEYOND THE PRICE

Track it. Plan it. Inspect it.

Select a strength and selection above to view price history, save a price watch or add it to your basket.

DOCUMENTATION PASSPORTS

Reports and batch records

Search all batch records

Inspect the source report, recorded lot and document access. A report link does not confirm the batch currently shipping.

Loading documentation records…

Listed amounts and selections

  • 10 mg1 supplier · Pack counts: 1, 10
  • 30 mg1 supplier · Pack counts: 1, 10
  • 60 mg1 supplier · Pack counts: 1, 10
  • 120 mg1 supplier · Pack counts: 1, 10
  • 150 mg1 supplier · Pack counts: 1, 10

Reported quantities in this family: 1, 10. Counts and units must be matched to the exact listing.

Compare the exact selection

Choose the labeled amount per unit and quantity before comparing. A single unit and a multipack have different upfront prices. Keep product format and exact recipe consistent; similar names do not establish equivalent products.

Follow the original listing to check its quantity, availability and current price. Unit prices use the full labeled mass in each selection.

Single-vial price overview

Compare within each strength. Every row covers one vial and includes only listings marked in stock with known quantities.

Listed total prices before additional promotions or coupon estimates. Includes supplier captures and aggregator reports; capture dates do not confirm current vendor price or stock. Shipping and tax extra. Open the source before relying on a price.
StrengthSelectionLowest listed total pricePrice per mgSupplier countCompare
10 mg1 vial$89.00$8.901Compare
30 mg1 vial$149.00$4.971Compare
60 mg1 vial$239.00$3.981Compare
120 mg1 vial$299.00$2.491Compare
150 mg1 vial$329.00$2.191Compare

Suppliers with Peptide 2 (T) listings

1 profiles

Sources and comparison limits

10 listings from direct supplier captures. Capture and import dates record when data was obtained; they do not guarantee the supplier’s current price or stock.

Listings include out-of-stock and unconfirmed-stock records. Inclusion does not certify a supplier, a batch or a product. Read how matching and source dates work.

Explore more vial listings

Browse all products

FROM PEPTIDES CALCULATOR

About Tirzepatide

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

Tirzepatide (LY3298176) is a once-weekly injectable peptide that activates both the GIP and GLP-1 receptors, a 39-amino-acid analog with a C20 fatty diacid side chain that binds albumin and gives it a half-life of 5 to 6 days. The FDA approved it in 2022 as Mounjaro for type 2 diabetes, then as Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity; the 2026 Mounjaro label also covers children from age 10. In the phase 3 program it lowered HbA1c by about 2 percentage points and beat semaglutide 1 mg in SURPASS-2, produced 20.9% mean weight loss at 72 weeks on 15 mg in SURMOUNT-1, and out-performed semaglutide 2.4 mg head to head in SURMOUNT-5. Both labels carry a boxed warning for thyroid C-cell tumors seen in rodents, and compounded or grey-market vials sold at concentrations from 5 to 20 mg/mL account for most of the dosing confusion documented online.

Formula
C225 H348 N48 O68
Molar mass
4,813 g/mol
Amino acids
39

Research evidence described in the source

Human

SURMOUNT-1 phase 3 trial

A 72-week randomized trial compared weekly 5, 10, and 15 mg doses with placebo in 2,539 adults without diabetes.

Human

Three-year follow-up

A prespecified population with obesity and prediabetes was followed through 176 weeks of treatment.

Review

Regulated dose ladder

The 2.5 mg initiation step is followed by 2.5 mg increments when clinically appropriate.

Limitations noted in the source

  • The 2.5 mg initiation dose is not a maintenance dose.
  • Risk, contraindication, and interaction information must come from current regulated labeling.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
Publications and references linked by the source

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.